压缩感知加速笛卡尔与径向动脉期肝脏成像在实验肿瘤模型中的个体内比较
研究在7只VX2肝肿瘤兔中个体内比较CS-VIBE与GRASP两种压缩感知加速MRI序列在肝血管期的动态成像表现,使用细胞外和肝细胞特异性对比剂。结果显示两序列整体图像质量无显著差异,CS-VIBE在钆塞酸增强时门静脉和肿瘤强化相对峰值信号更高,GRASP序列特异性伪影更多但不影响图像质量。
要点
- CS-VIBE与GRASP在动态肝脏MRI中整体图像质量相当,均可获得最多4个肝动脉优势期。
- 钆塞酸增强时CS-VIBE门静脉和肿瘤强化相对峰值信号显著高于GRASP。
- GRASP序列特异性伪影更多,但未影响图像质量评级。
关键影像表现/征象
- 两序列整体图像质量评为中等至优秀,无显著差异。
- 钆布醇增强CS-VIBE血管 delineation 和肿瘤强化 Likert 评分最高:动脉4.4(4-5)、静脉4.3(3-5)、肿瘤2.9(2-3)。
- GRASP序列特异性伪影显著更多(P=0.008-0.031),但未损害图像质量。
- 两序列运动伪影评分均优秀,最多获得4个肝动脉优势期。
诊断标准与关键数值
- 相对峰值信号增强在主动脉、肝动脉、下腔静脉两序列无显著差异(P=0.063-0.536)。
- 钆塞酸增强时CS-VIBE门静脉相对峰值信号显著更高(P=0.031)。
- 钆塞酸增强时CS-VIBE肿瘤强化相对峰值信号显著更高(P=0.005)。
- 达峰时间、平均通过时间及血浆流量比两序列无显著差异。
临床应用与阅片要点
- CS-VIBE在钆塞酸增强时对门静脉和肿瘤强化显示更优,可优先用于肝细胞特异性对比剂动态增强。
- GRASP序列特异性伪影较多但未影响图像质量,阅片时注意识别但不需因此降低诊断信心。
- 两序列均可获得多个肝动脉优势期,有利于多期动态观察。
局限性
- 样本量小(仅6只动物完成全方案并分析)。
- 为动物实验研究,结论向临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to intraindividually compare the performance of 2 compressed sensing (CS)-accelerated magnetic resonance imaging (MRI) sequences, 1 featuring Cartesian (compressed sensing volumetric interpolated breath-hold examination [CS-VIBE]) and the other radial (golden-angle radial sparse parallel [GRASP]) k-space sampling in continuous dynamic imaging during hepatic vascular phases, using extracellular and hepatocyte-specific contrast agents.
MATERIALS AND METHODS: Seven New Zealand white rabbits, with induced VX2 liver tumors (median number of lesions, 2 ± 0.83; range, 1-3), received 2 continuously acquired T1-weighted prototype CS-accelerated MRI sequences (CS-VIBE and GRASP) with high spatial (0.8 × 0.8 × 1.5 mm) and temporal resolution (3.5 seconds) in randomized order on 2 separate days using a 1.5-T scanner. In all animals, imaging was performed using first gadobutrol at a dose of 0.1 mmol/kg and, then 45 minutes later, gadoxetic acid at a dose of 0.025 mmol/kg.The following qualitative parameters were assessed using 3- and 5-point Likert scales (3 and 5 being the highest scores respectively): image quality (IQ), arterial and venous vessel delineation, tumor enhancement, motion artifacts, and sequence-specific artifacts. Furthermore, the following quantitative parameters were obtained: relative peak signal enhancement, time to peak, mean transit time, and plasma flow ratios. Paired sampled t tests and Wilcoxon signed rank tests were used for intraindividual comparison. Image analysis was performed by 2 radiologists.
RESULTS: Six of 7 animals underwent the full imaging protocol and obtained data were analyzed statistically. Overall IQ was rated moderate to excellent, not differing significantly between the 2 sequences.Gadobutrol-enhanced CS-VIBE examinations revealed the highest mean Likert scale values in terms of vessel delineation and tumor enhancement (arterial 4.4 [4-5], venous 4.3 [3-5], and tumor 2.9 [2-3]). Significantly, more sequence-specific artifacts were seen in GRASP examinations (P = 0.008-0.031). However, these artifacts did not impair IQ. Excellent Likert scale ratings were found for motion artifacts in both sequences. In both sequences, a maximum of 4 hepatic arterial dominant phases were obtained. Regarding the relative peak signal enhancement, CS-VIBE and GRASP showed similar results. The relative peak signal enhancement values did not differ significantly between the 2 sequences in the aorta, the hepatic artery, or the inferior vena cava (P = 0.063-0.536). However, significantly higher values were noted for CS-VIBE in gadoxetic acid-enhanced examinations in the portal vein (P = 0.031) and regarding the tumor enhancement (P = 0.005). Time to peak and mean transit time or plasma flow ratios did not differ significantly between the sequences.
CONCLUSIONS: Both CS-VIBE and GRASP provide excellent results in dynamic liver MRI using extracellular and hepatocyte-specific contrast agents, in terms of IQ, peak signal intensity, and presence of artifacts.
引用
- Harder FN, Budjan J, Nickel MD, et al. Intraindividual Comparison of Compressed Sensing-Accelerated Cartesian and Radial Arterial Phase Imaging of the Liver in an Experimental Tumor Model. Invest Radiol. 2021. PMID: 33813577. doi:10.1097/RLI.0000000000000767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。